These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 576870)

  • 1. Plasma thyroxine, 3,3',5-triiodothyronine and 3,3',5'-triiodothyronine during beta-adrenergic blockade in hyperthyroidism.
    Verhoeven RP; Visser TJ; Doctor R; Hennemann G; Schalekamp MA
    J Clin Endocrinol Metab; 1977 May; 44(5):1002-5. PubMed ID: 576870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3'5-triiodothyronine (T3).
    Chopra IJ; Williams DE; Orgiazzi J; Solomon DH
    J Clin Endocrinol Metab; 1975 Nov; 41(5):911-20. PubMed ID: 1242390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
    N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid function tests during carbimazole therapy.
    Scott DL; Tymms DJ; Taylor MA; Chapman C
    Postgrad Med J; 1980 Dec; 56(662):838-41. PubMed ID: 6894979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
    Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
    J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasmatic thyroid hormones during treatment of hyperthyroidism by carbimazol (author's transl)].
    Linquette M; Lefebvre J; Benoit G; Racadot A
    Ann Endocrinol (Paris); 1977; 38(2):169-70. PubMed ID: 578398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease.
    Takamatsu J; Kuma K; Mozai T
    J Clin Endocrinol Metab; 1986 May; 62(5):980-3. PubMed ID: 3754263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum thyroid hormones and TSH response to TRH during treatment of Graves' disease by carbimazole (author's transl)].
    Lorcy Y; Heim J; Auvray E; Allannic H
    Ann Endocrinol (Paris); 1979; 40(4):441-2. PubMed ID: 117739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content.
    Larsen PR
    J Clin Endocrinol Metab; 1975 Dec; 41(06):1098-104. PubMed ID: 54364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: effects on recurrence of hyperthyroidism and thyroid volume.
    Pfeilschifter J; Ziegler R
    Eur J Endocrinol; 1997 Jan; 136(1):81-6. PubMed ID: 9037131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propranolol and hyperthyroidism: sequential changes in serum iodothyronine (T4, T3, rT3) concentrations during therapy until clinical remission.
    Pinho MO; Medeiros YS; Rosenthal D; Francalanci CC
    Braz J Med Biol Res; 1983 Jul; 16(2):111-7. PubMed ID: 6652288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy.
    Mastorakos G; Doufas AG; Mantzos E; Mantzos J; Koutras DA
    J Endocrinol Invest; 2003 Oct; 26(10):979-84. PubMed ID: 14759070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of long-term antithyroid drug treatment on serum reverse T3 in patients with Graves' disease.
    Dahlberg PA; Karlsson FA; Wide L
    Acta Med Scand; 1980; 207(5):375-8. PubMed ID: 6155758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease.
    MacFarlane IA; Davies D; Longson D; Shalet SM; Beardwell CG
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):557-61. PubMed ID: 6411390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictor of outcome of hyperthyroidism due to Graves disease: serum triiodothyronine/thyroxine ratio.
    Khanna CM; Shankar LR; Jaggi CB; Bansal JK; Chugh P
    J Assoc Physicians India; 1996 Feb; 44(2):98-101. PubMed ID: 10999059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid hormone metabolism in thyroid disease as reflected by the ratio of serum triiodothyronine to thyroxine.
    Erfurth EM; Hedner P
    J Endocrinol Invest; 1986 Oct; 9(5):407-12. PubMed ID: 3794185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term treatment of Graves' hyperthyroidism with sodium ipodate.
    Shen DC; Wu SY; Chopra IJ; Huang HW; Shian LR; Bian TY; Jeng CY; Solomon DH
    J Clin Endocrinol Metab; 1985 Oct; 61(4):723-7. PubMed ID: 3928675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of thyroid hormone and methimazole levels in patients with Graves' disease on a standardized anti-thyroid drug regimen.
    Dahlberg PA; Karlsson FA; Lindström B; Wide L
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):555-62. PubMed ID: 6895351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further studies on the long-term treatment of Graves' hyperthyroidism with ipodate: assessment of a minimal effective dose.
    Shen DC; Wu SY; Chopra IJ; Shian LR; Florsheim W; Solomon DH
    Thyroid; 1991; 1(2):143-6. PubMed ID: 1822359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of beta-adrenoceptor blocking agents on plasma thyroxine and triiodothyronine.
    Wiersinga WM; Touber JL
    J Clin Endocrinol Metab; 1977 Aug; 45(2):293-8. PubMed ID: 885993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.